Anxiolytic Effect of Melatonin in Premenstrual Dysphoric Disorder

Increases in anxiety levels during the late-luteal phase of the menstrual cycle form important diagnostic criteria of premenstrual dysphoric disorder (PMDD) (1). Evidence exists to support the hypothesis that tolerance to endogenous levels of melatonin might occur during the luteal phase in PMDD (2, 3). It was hypothesized that slow release (SR) melatonin administration during the luteal phase of the menstrual cycle of participants with PMDD could significantly lower anxiety levels measured by self-report

Subjective Assessment of Sleep Quality Across the Menstrual Cycle in Women with Premenstrual Dysphoric Disorder

Existing evidence demonstrates that sleep structure varies across the menstrual cycle in healthy women (1). These variations could be more severe in women suffering from premenstrual dysphoric disorder (PMDD) (2). In a previous study of healthy women, subjective sleep quality was shown to be constant across both phases of the menstrual cycle (3). The current study aims to test whether there exists a variation in subjective sleep quality of PMDD sufferers across the follicular and luteal phases of the menstrual cycle